Anticancer agents in regulation of metabolites

New anticancer agents are in great demand due to the heterogeneous nature of cancer and the development of resistance to existing drugs. This collaborative research between Robert Weiss, biomedical sciences, Richard Cerione, molecular medicine, and Hening Lin, chemistry & chemical biology, aims to establish SIRT5 inhibition as a new strategy to treat cancers.

SIRT5 is a key regulator of several metabolic proteins upon which cancer cells are dependent. Weiss, Cerione and Lin are determining how blocking SIRT5 inhibits malignant transformation and tumorigenesis. They are working to understand the detailed molecular functions of SIRT5 in cancer cells, as well as in the tumor microenvironment.The researchers received a $1.95 million grant spanning five years to continue their research on this unique regulator.

The discoveries will provide knowledge that can help improve the development of novel therapeutics for treating cancer.

Read more about the research and grant on Cornell Research.

More news

View all news